Shares of clinical-stage biotechnology company Anavex Life Sciences (NASDAQ: AVXL) recently shot higher. Investors reacting to great news for its Alzheimer's disease drug candidate, blarcamesine, drove the stock about 40% higher when the market opened on Friday, Dec. 2.
Unfortunately, the big gain started to fizzle shortly after the market opened. This left investors who were cheering the positive results feeling more than a little confused.
Is Anavex Life Sciences a smart stock to buy now, or will the road ahead be a rocky one full of potholes? Let's start by looking at the results Anavex touted as successful.
For further details see:
Is Anavex Life Sciences a Smart Stock to Buy Now?